Castañeda GP, Eljure TJ

Idioma: Español
Referencias bibliográficas: 25
Paginas: 6-14
Archivo PDF: 225.64 Kb.

RESUMEN

El cáncer de piel es uno de los tumores con mayor incidencia en el ser humano, por lo que se le debe de dar la importancia que se merece en la enseñanza del médico general, ya que en la mayoría de los casos es prevenible y curable. Existen dos tipos de cáncer de piel: el no melanoma, que se compone por el carcinoma basocelular y el espinocelular, y el melanoma. El pronóstico de curación dependerá de la detección precoz y la correcta extirpación.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gutiérrez Vidrio RM. Cáncer de piel. Rev Fac Med UNAM. 2003;46(4):166-71.

2. Marzuka AG, Book SE. Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management. The Yale Journal of Biology and Medicine. 2015;88(2):167-79.

3. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000 Prime Reports. 2015;7:53. doi: 10.12703/P7-53.

4. Robinson JK. Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer. 1987;60(1):118.

5. Van Dam RM, Huang Z, Rimm EB, Weinstock MA, Spiegelman D, Colditz GA, et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol. 1999;150(5):459.

6. Kennedy C Bajdik CD, Willemze R, de Gruijl FR, Bouwes Bavinck J, for the members of the Leiden Skin Cancer Study. The Infuence of Painful Sunburns and Lifetime Sun Exposure on the Risk of Actinic Keratoses, Seborrheic Warts, Melanocytic Nevi, Atypical Nevi, and Skin Cancer. Journal of Investigative Dermatology. 2003;120:1087-93.

7. Boonchai W, Green A, Ng J, Dicker A, Chenevix-Trench G. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. J Am Acad Dermatol. 2000;43(4):664.

8. Gallagher RP, Hill GB, Bajdik CD, Fincham S, Coldman AJ, McLean DI, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131(2):157.

9. Metterle L, Russell JS, Patel NS. An overview of the medical management of nonmelanoma skin cáncer. Curr Probl Cancer. 2015;39(4):226-36.

10. Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight-induced immunosuppression in human beings. Am J Am Acad Dermatol. 2008;58 (Suppl 2):S149-S154.

11. Hanneman KK, Cooper KD, Baron ED. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin. 2006;24(1):19-25.

12. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4-7.

13. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40 (2 Pt 1):177-86.

14. Amado S. Lecciones de dermatología. 15ª edición, México: Méndez editores; 2008. 666-93.

15. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4): 759-65.

16. Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nature Rev Dis Primers. 2015;1:1-20.

17. Voss RK, Woods TN, Cromwell KD, Nelson KC, Cormier JN. Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis. Patient Related Outcome Measures. 2015;6:229-242.

18. Dummer R, Hauschild A, Guggenheim M, Keilholz U & Pentheroudakis G, on behalf of the ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 (suppl 7):vii86-vii91.

19. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Front Biosci 2006;11:1244-54.

20. Mogensen M, Jemec GB. The potential carcinogenic risk of tanning beds: clinical guidelines and patient safety advice. Cancer Manag Res. 2010;2:277-82.

21. Tsao H, Atkins MB, Sober AJ. Management of Cutaneous Melanoma; N Engl J Med. 2004;351:998-1012.

22. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292:2771-6.

23. Grob JJ, Bonerandi JJ. The ‹ugly duckling› sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134(1):103-4.

24. Sabel MS, Wong SL. Review of evidence-based support for pretreatment imaging in melanoma. J Natl Compr Canc Netw. 2009;7(3):281-9.

25. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129-42.